To hear about similar clinical trials, please enter your email below
Trial Title:
Analysis of Circulating Exosomes in Melanoma Patients
NCT ID:
NCT05744076
Condition:
Melanoma
Conditions: Official terms:
Melanoma
Study type:
Observational
Overall status:
Active, not recruiting
Study design:
Time perspective:
Other
Summary:
The hypothesis is that PD-L1[Programmed Death-Ligand 1] labeling in exosomes could be a
biomarker of disease progression in melanoma. The rate of circulating exosomes, their
size and the exosomal expression of PD-L1 could be correlated with the stage of the
disease, the response to treatment and/or the prognosis of patients. In this study, blood
samples (EDTA tubes taken as part of routine care at Besançon University Hospital) and
associated clinical data are reused.
Criteria for eligibility:
Study pop:
Melanoma patients admitted in Besançon University Hospital
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- Melanoma patients admitted in Besançon University Hospital
- exigible for immunotherapy such as anti PD-L1/PD-1
- Age ≥18 years
- Affiliation to a social security system,
Exclusion Criteria:
- Minor patients
- Patients who have expressed their opposition to the reuse of their data and
biological samples
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
CHU de Besançon
Address:
City:
Besançon
Country:
France
Start date:
March 1, 2019
Completion date:
March 2024
Lead sponsor:
Agency:
Centre Hospitalier Universitaire de Besancon
Agency class:
Other
Collaborator:
Agency:
Centre Georges Francois Leclerc
Agency class:
Other
Source:
Centre Hospitalier Universitaire de Besancon
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05744076
